NEIL Boyle, the former managing director of Merck Sharpe Dohme's operation in Ireland, has formally resigned as a director of the operation after being promoted to head up the company's global pain management product range, based in New Jersey.
Mr Boyle headed Merck Sharpe Dohme (MSD) Ireland (human health) from 2007 until just a few weeks ago. He was previously medical director with the Irish arm and joined MSD from Wyeth, where he worked for a year, also as medical director.
MSD's human health division in Ireland is based in south Dublin. It employs over 2,300 people at sites in the capital, Carlow, Cork, Tipperary and Wicklow.
It is one of Ireland's biggest exporters and manufactures a range of products from prescription medicines to vaccines and biologic therapies.
The company was acquired by Schering Plough in 2009 in a $41bn (€30.9bn) deal.
In October, MSD announced that it plans to lay off 90 staff at a facility in Cork – where there are over 450 people employed –by April. MSD said it wasn't initiating the redundancies due to any lack of demand for its products, but because the plant already had sufficient supplies of active ingredients in stock.
Filings at the Companies Office indicate that Mr Boyle formally resigned his directorship at MSD's Irish arm just this month. Filings also indicate that Brian Longstreet, who is currently listed as MSD's vice president, west commercial operations group in the US, has been appointed a director of the Irish business.
They also note the appointment of another company executive, Fabrizio Agressi, as a director of the Irish unit.